Drug Profile

Dronabinol - Michael James Enterprises

Latest Information Update: 22 Feb 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator RP Capital Group
Developer Michael James Enterprises; University of Illinois at Chicago
Class Antidementias; Antiemetics; Antineoplastics; Appetite stimulants; Cannabinoids; Chromans; Muscle relaxants; Non-opioid analgesics; Small molecules
Mechanism of Action Cannabinoid receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Sleep apnoea syndrome

Most Recent Events

22 Feb 2022 Discontinued - Phase-II for Sleep apnoea syndrome in USA (PO)
05 Aug 2016 Michael James Enterprises acquires dronabinol from RP Capital Group
05 Aug 2016 Phase-II clinical trials in Sleep apnoea syndrome in USA (PO) before August 2016

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com